Sort by

Send to

Choose Destination

Search results

Items: 4


Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.

Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.

J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.


The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines.

Dubois C, Daumar P, Aubel C, Gauthier J, Vidalinc B, Mounetou E, Penault-Llorca F, Bamdad M.

J Clin Med. 2019 Mar 21;8(3). pii: E397. doi: 10.3390/jcm8030397.


Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.

Daumar P, Dufour R, Dubois C, Penault-Llorca F, Bamdad M, Mounetou E.

J Pharm Biomed Anal. 2018 Apr 15;152:74-80. doi: 10.1016/j.jpba.2018.01.036. Epub 2018 Jan 31.


Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M.

Oncotarget. 2017 Aug 24;8(56):95316-95331. doi: 10.18632/oncotarget.20517. eCollection 2017 Nov 10.

Supplemental Content

Loading ...
Support Center